Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma: Identification of New Therapeutic Targets
Institut Paoli-Calmettes
64 participants
Sep 11, 2025
OBSERVATIONAL
Conditions
Summary
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers. Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Eligibility
Inclusion Criteria15
- Age > 18 years
- Signed written informed consent specific to the PROMETAP study
- Affiliation with a social security system
- Treatment and follow-up performed at the Institut Paoli-Calmettes
- Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
- Prior treatment:
- No previous chemotherapy for the "initial" group
- No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
- Eligible for chemotherapy (ECOG < 2)
- Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
- Absence of a metastasis accessible to biopsy (group1 and 2)
- Concurrent treatment for another active cancer
- Pregnant or breastfeeding women
- Patients in emergency situations
- \. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Tumor cells isolation
Isolation of blood monocytes
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07664891